Reinventing our medical R&D system

Safeguarding universal access to medicines in the EU and in the world

WATCH THE RECORDED VIDEO OF THE EVENT

INTRODUCTION

The prices of new life-saving medicines have never been so high in the EU, putting our social security models, universal rights to care-access and national budgets at risk. Poor countries don't have the monopoly of care exclusion anymore. Who is responsible for this situation? More and more stakeholders point at our broken R&D model in the pharmaceutical sector: less real and needed innovation, less return on investment for publicly funded research because of private patenting and privatized benefits, more short-term pressure from the shareholders in the care sector. So what can be done at EU level? This is what you will hear in this conference.

AGENDA

9:30-10:40

Part I: overview of the current situation that leads to unaffordable medicines
(chair: Michèle Rivasi MEP)

introduction by the Chair
presentation of the situation in Greece, by Panagiotis Kouroumplis, the Greek minister for health
presentation of the situation in Spain, by Elodie Besnier from Salud por Derecho
presentation of the situation in Germany, by Joerg Schaaber from BUKO Pharma-Kampagne
Q&A session
closing remarks by the Chair

10:40-11:50

Part II: analysis of the roots of the current problems
(chair: Ernest Maragall MEP)

introduction by the Chair
Comparison of the current situation in the EU and worldwide, by Helle Aagaard from MSF
Pharmaceutical research and market failures: a guideline, by Ignasi Belda, president and founder of Intelligent Pharma
The cost of medical research and the lack of transparency, by Gaëlle Krikorian, sociologist and intellectual property rights expert
Q&A session
closing remarks by the Chair

11:50-13:00

Part III: the possible solutions
(chair Michèle Rivasi)